A published phase 2 study reported that lonafarnib was administered as a single agent via
continuous or intermittent oral dosing to 76 women with advanced breast cancer who were
previously treated with chemotherapy and/or with endocrine therapy. Objective response rates
of approximately 10% were observed. This study will determine the rate of progression-free
survival of patients with metastatic breast cancer who receive lonafarnib.